Adaptive Biotechnologies

Adaptive Biotechnologies

Yahoo Finance • 18 days ago

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company's clonoSEQ assay... Full story

Yahoo Finance • 19 days ago

NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-clear... Full story

Yahoo Finance • 26 days ago

10 mid-cap healthcare stocks with the strongest momentum grades

Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum... Full story

Yahoo Finance • 3 months ago

Cathie Wood reshuffles portfolio ahead of Q2, buys SpaceX, Eli Lilly, Meta; pares AMD, Roku

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52... Full story

Yahoo Finance • 3 months ago

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Harlan S. Robins, the chief scientific officer of Adaptive Biotechnologies Corporation (NASDAQ:ADPT), sold 386,240 shares of common stock at $22.01 per share on July 2, 2026, according to an SEC Form 4 filing. Transaction summary Metric... Full story

Yahoo Finance • 3 months ago

Global Hematologic Malignancies Testing Market Size/Share Worth USD 12.47 Billion by 2035 at a 14.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Hematologic Malignancies Testing Market size & share revenue was valued at approximat... Full story

Yahoo Finance • 4 months ago

BTIG Maintains a Buy Rating on Adaptive Biotechnologies (ADPT)

​Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the Best Growth Stocks to Buy and Hold for the Next Decade. On June 17, BTIG maintained a Buy rating on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) with a $22 price targe... Full story

Yahoo Finance • 4 months ago

At a glance: stocks gapping down premarket

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Tuesday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) were muted on Tu... Full story

Yahoo Finance • 4 months ago

Biggest stock movers Tuesday: SPCX, QCOM, and more

[Emerging Financial Data - Stock Market, Prosperity, Bull Market - Blue Version] DKosig Stock futures were muted on Tuesday while oil prices continued to drift downward. Wall Street went into a waiting mode as investors looked for more co... Full story

Yahoo Finance • 6 months ago

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corporation(NASDAQ:ADPT), reported the direct sale of 57,180 shares of Common Stock—following option exercise—across multiple transactions from April 9 through April 13, 2026,... Full story

Yahoo Finance • 6 months ago

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

Key Points 57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, reducing her directly held C... Full story

Yahoo Finance • 6 months ago

Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings

[Heart Health Concept] Eoneren/E+ via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary laggards, with the Health Care Select Sector SPDR Fund (XLV [https://se... Full story

Yahoo Finance • 6 months ago

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On

Julie Rubinstein, the President and COO of Adaptive Biotechnologies Corporation(NASDAQ:ADPT), reported the sale of 38,120 shares of Common Stock for approximately $554,000 in a set of transactions executed on April 1, 2026 and April 2, 202... Full story

Yahoo Finance • 7 months ago

Is Merck & Co., Inc. (MRK) A Good Stock To Buy Now?

Is MRK a good stock to buy now? We came across a bullish thesis on Merck & Co., Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc.'s share was trading at $117.11 as of March 9th.... Full story

Yahoo Finance • 8 months ago

Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, w... Full story

Yahoo Finance • 8 months ago

Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ...

This article first appeared on GuruFocus. Total Revenue: $277 million for the full year, representing 55% year-over-year growth. MRD Revenue: $212 million for the full year, up 46% year-over-year. Immune Medicine Revenue: $23.4 million fo... Full story

Yahoo Finance • 9 months ago

Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies SEATTLE, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clini... Full story

Yahoo Finance • 10 months ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Adaptive Biotechnologies A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and developm... Full story

Yahoo Finance • 10 months ago

Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease

SEATTLE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story

Yahoo Finance • 10 months ago

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose... Full story